ETI-210

ETI-210 is a selective, brain-penetrant small molecule inhibitor of cyclin-dependent kinase 2 (CDK2) being developed by Eilean Therapeutics for the treatment of solid tumors. CDK2 is a critical regulator of the cell cycle, specifically the G1/S phase transition, and its dysregulation is a common driver in various malignancies, including CCNE1-amplified ovarian, breast, and endometrial cancers. ETI-210 is designed to provide potent and selective inhibition of CDK2 to minimize off-target toxicities associated with pan-CDK inhibition. A key differentiator of ETI-210 is its ability to cross the blood-brain barrier, which potentially enables the treatment of primary brain tumors and brain metastases, addressing a significant unmet need in oncology.

Other names

Selective Brain Penetrant CDK2 InhibitorCDK2 inhibitor (Eilean Therapeutics)CDK2 inhibitor-Eilean Therapeutics Australia-CDK2-small molecule inhibitor-Solid TumorsCDK-2 inhibitor-Eilean Therapeutics Australia-CDK2-small molecule inhibitor-Solid TumorsCDK 2 inhibitor-Eilean Therapeutics Australia-CDK2-small molecule inhibitor-Solid Tumors